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Institute ofDigestive Diseases, Department ofSurgery, Belgrade University School ofMedicine, Koste Todorovica 6, Belgrade
11000, Yugoslavia.
It has been recently shown that gastric cancer patients have
higher circulating gastrin levels than control subjects (Rakic
et al., 1991). We measured fasting serum gastrin in patients
with gastric cancer in an attempt to define whether any
difference could be demonstrated according to the histologic
type of tumour.
The study population consisted of 61 patients with histo-
logically proven gastric cancer and 26 normal subjects. Those
with a potential cause for hypergastrinemia were excluded
from the study. Gastric cancer patients were classified ac-
cording to the criteria of Lauren (Lauren, 1965) as diffuse
(n = 20) or intestinal type (n = 41). Venous blood samples
were obtained with consent from each subject after an over-
night fast. Serum gastrin levels were determined in unhep-
arinised serum by radioimmunoassay using a commerical kit
from Oris Industrie (Gif-Sur-Yvette, France). The antiserum
used in the assay presents a correct recognition of G-17. The
statistical analysis was done utilising the ANOVA (age), and
Mann-Whitney tests (serum gastrin levels).
The groups were well matched for age. The gastrin levels
in pg ml' for the three groups are shown in Table I. The
gastrin levels in patients with intestinal gastric cancer and
diffuse gastric cancer were significantly higher than in con-
trols (P<0.00001 and P<0.01 respectively). The mean and
median gastrin levels in patients with intestinal gastric cancer
were higher than in patients with diffuse gastric cancer,
although the difference did not reach statistical significance
(P = 0.07). Elevated mean gastrin levels in patients with
Table I Serum gastrin levels in patients with diffuse and intestinal -
type gastric carcinoma
Control Difuse Intestinal
(n = 26) (n = 20) (n = 41)
Mean 36.7 59.6 115.6
s.d. 9.8 38.6 157.8
Median 36.8 45.4 68.2
Range 23.2-54.6 29.2-184.9 23.3-851.7
intestinal gastric cancer was primarily due to a subgroup of
26 patients (63%) with higher gastrin levels than the control
group mean + 2 s.d. level (55.3 pg ml-'). Only seven patients
(35%) with diffuse gastric cancer had higher gastrin levels
than the control group mean gastrin level + 2 s.d.
We have shown that hypergastrinemia is associated with
gastric cancer, particularly of the intestinal type. It is not
clear whether hypergastrinemia is the cause or effect of the
tumour or the result of an event such as achlorhydria. It has
been previously shown that the prevalence of atrophic gastri-
tis and a/hypochlorhydria is higher in patients with intestinal
gastric cancer (64%) than in patients with diffuse gastric
cancer (29%) (Sipponen et al., 1983). This is a similar pro-
portion to the one we found for patients with elevated gast-
rin levels, which may account for the difference in gastrin
levels observed in this study.
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